SRL
UNCY icon

Scientech Research LLC’s Unicycive Therapeutics UNCY Stock Holding History

Scientech Research LLC’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$349K Buy
+74,490
New +$549K 0.28% 107
2024
Q3 		– Sell
-1,097
Closed -$5.5K – 851
2024
Q2 		$5.5K Buy
+1,097
New +$10.8K ﹤0.01% 562

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Scientech Research LLC's UNCY Position: Q2 2026 in Review

Scientech Research LLC opened a new position in Unicycive Therapeutics (UNCY) in Q2 2026: 74,490 shares worth $349K. The stake represents 0.28% of the portfolio and ranks #107 among its holdings. This is a return to the name: Scientech Research LLC previously reported a position in UNCY as recently as Q2 2024.

Scientech Research LLC first reported a position in UNCY in Q2 2024 and has held it in 2 quarters since. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Scientech Research LLC held 74,490 shares of Unicycive Therapeutics worth $349K as of Q2 2026.
  • Unicycive Therapeutics was a new Scientech Research LLC position in Q2 2026.
  • Unicycive Therapeutics made up 0.28% of Scientech Research LLC's portfolio in Q2 2026, its #107 holding.
  • Scientech Research LLC first reported a position in Unicycive Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Scientech Research LLC's 13F filing for Q2 2026, filed 14 Aug 2026.